# Halozyme Therapeutics share price today (Halozyme Therapeutics, Inc., HALO)

> Halozyme Therapeutics, Inc.'s share price has risen faster than its earnings: +80.2% in a year, against −25.4% for earnings per share. HALO · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/halo

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Mixed, from the last 12 quarters
- Price: $122.96 (+80.2% in a year)
- P/E: 36.4× (higher than 95% of the last 4.6 years)
- Revenue (Jun 2026): $481 M (+47.7% on a year ago)
- Profit (Jun 2026): $230 M (+39.2% on a year ago)
- Operating margin: 59.8% (−2.4 points on a year ago)
- ROE: 649%, FY25
- ROIC: 32.1%, against a 7.9% cost of capital: +24.2 points

The main question: the share price moved +80.2% in a year while yearly earnings per share moved −25.4%. The difference came from the market paying a higher multiple. ## What is the Halozyme Therapeutics share price today? Halozyme Therapeutics, Inc.'s share price was $122.96 at the close on 5 November 2026. It has been rising for 20 weeks. That is 45.5% above its average price over the last 200 trading days. In the last 52 weeks it traded between $62 and $131, and at that close it sat 89% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 20 weeks in a row. Over the last 10 years the share price moved +1,250% while the S&P 500 moved +245%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Halozyme Therapeutics pay? Halozyme Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Halozyme Therapeutics on? Halozyme Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Halozyme Therapeutics profitable? Halozyme Therapeutics, Inc. earned $230 M of net profit in the Jun 2026 quarter, +39.2% on the same quarter a year earlier. That is the 2nd quarter in a row of profit growth. Full-year FY25 profit was $317 M. Over 4 years profit has grown −5.8% a year on average. That is 47.8% of the quarter's revenue. The same quarter a year earlier earned $165 M. 1 of the last 12 reported quarters were loss-making. For the full year, FY25 profit was $317 M (−28.6% on the year before). Why profit moved: revenue changed +47.7% on a year earlier and the margin moved −2.4 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −27.3% and revenue +40.9%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Halozyme Therapeutics make, and is it growing? Halozyme Therapeutics, Inc. reported $481 M of revenue in the Jun 2026 quarter, +47.7% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 4 years it has grown 33.2% a year on average. The last full year, FY25, came in at $1.4 B. The last four reported quarters add to $1.7 B. FY25 revenue was $1.4 B, +37.6% on the year before. Recent pace: the last four quarters grew +40.9% on average, against 33.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +41.2%, against +38.0% a year over the last 8 quarters (accelerating); profit over the last 12 months grew −25.8%, against +10.7% a year (rolling over). ## How much of every $100 of sales does Halozyme Therapeutics keep? Halozyme Therapeutics, Inc.'s operating margin was 59.8% in the Jun 2026 quarter, 2.4 percentage points lower than the same quarter a year ago. Across 5 years it has been between 40.7% and 62.2%. The latest quarter is within that range. Why the margin moved: operating margin changed −2.4 percentage points on the year while gross margin changed −2.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Halozyme Therapeutics' profit turning into cash? Over the last 3 years, 146% of Halozyme Therapeutics, Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 it brought in $652 M of operating cash against $317 M of profit. After $7.0 M of spending on assets, $645 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Halozyme Therapeutics' cash go? Halozyme Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $33.0 M on assets over the last 3 years. Averaged over those years that is 0.8% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $33.0 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Halozyme Therapeutics' P/E ratio, and how does it compare with its own history? Halozyme Therapeutics, Inc.'s P/E is 36.4×, near the high end of its own history: higher than 95% of past readings. Its usual P/E (the middle reading) is 20.2×, over 4.6 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Why the multiple is where it is: over the past year earnings per share moved −25.4% while the price moved +80.2%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 3 years the price moved +51.2% a year; about +21.1% a year came from earnings growth and about +30.1 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Halozyme Therapeutics business getting better or worse? Halozyme Therapeutics, Inc.'s business is giving mixed signals. Profit and EPS growth are shrinking while ROCE is still rising at 45.5%, so growth and returns point different ways. This is based on 12 quarters of 4 measures. Why it matters: when the lines disagree, each line above matters more than any single label. ## How much does Halozyme Therapeutics earn on its capital? Halozyme Therapeutics, Inc. earned a ROE of 649% in FY25. That is up from a low of 119% in FY22. Its return on capital used (ROIC) is 24.2 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 22.7% net margin and 0.55× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 22.7% net margin × 0.55× asset turnover × 51.73× leverage (assets divided by equity) ≈ 645.8% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 32.1% − 7.9% = +24.2 percentage points. The 7.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value. ## Does Halozyme Therapeutics have too much debt? Halozyme Therapeutics, Inc. has total debt of $2.2 B against shareholder equity of $144 M as of Jun 2026, so its debt is 15.18× its equity. Year by year, that ratio went from 4.47 in FY21 to 44.60 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Halozyme Therapeutics shareholding pattern? 12.2% of Halozyme Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Halozyme Therapeutics from balance-sheet trouble? For Halozyme Therapeutics, Inc., the Z-score is 4.19. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 4.19 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Halozyme Therapeutics rank in its industry? 72.0 out of 100, rank 2 of 30 in Biotechnology, with 81% of the evidence available. Halozyme Therapeutics, Inc. scores 72.0 out of 100 against the 30 companies it is compared with in Biotechnology, ranking 2. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 17.7 + 20.9 + 14.6 + 18.8 = 72. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Halozyme Therapeutics compared with? Halozyme Therapeutics ranks 2 of 30 Biotechnology companies on the 4-Factor Sector Score, with 72.0 out of 100. 1. [Exelixis, Inc.](https://www.sectoralpha.in/us/stocks/exel) EXEL · breaking out · Most evidence points up · 81% evidence 76.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.7/35 · Revenue 9.3% · Profit 42.8% · Operating margin change 1.9 points · 83% evidence Capital efficiency 20.9/25 · ROCE 46.5% · Operating margin 39.5% · 76% evidence Valuation 14.6/20 · P/E 15.9× · PEG 0.3 · 65% evidence Relative strength 17.9/20 · Lead over its industry 9.7% · Lead over S&P 500 35.4% · 1 year 68.4% · 100% evidence · 8 of 12 weeks ahead Exact sum: 22.7 + 20.9 + 14.6 + 17.9 = 76.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. Halozyme Therapeutics, Inc. this page HALO · leader · Most evidence points up · 81% evidence 72.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.7/35 · Revenue 41.1% · Profit -25.9% · Operating margin change -2.4 points · 83% evidence Capital efficiency 20.9/25 · ROCE 42.3% · Operating margin 59.8% · 76% evidence Valuation 14.6/20 · P/E 22.4× · PEG 0.25 · 65% evidence Relative strength 18.8/20 · Lead over its industry 21.7% · Lead over S&P 500 48.8% · 1 year 80.2% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.7 + 20.9 + 14.6 + 18.8 = 72 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Incyte Corporation](https://www.sectoralpha.in/us/stocks/incy) INCY · turning · Most evidence points up · 71% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.1/35 · Revenue 26.9% · Profit 85.3% · Operating margin change 16.3 points · 83% evidence Capital efficiency 20.5/25 · ROCE 28.1% · Operating margin 41.9% · 76% evidence Valuation 10.9/20 · P/E 14× · PEG n/a · 15% evidence Relative strength 7.2/20 · Lead over its industry -12.7% · Lead over S&P 500 8.2% · 1 year 11.4% · 100% evidence · 5 of 12 weeks ahead Exact sum: 27.1 + 20.5 + 10.9 + 7.2 = 65.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Genmab A/S](https://www.sectoralpha.in/us/stocks/gmab) GMAB · leader · Evidence leans up · 81% evidence 61.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 11.0/35 · Revenue 18.2% · Profit -39.3% · Operating margin change -3.7 points · 83% evidence Capital efficiency 15.6/25 · ROCE 11.7% · Operating margin 35.2% · 76% evidence Valuation 15.1/20 · P/E 21.4× · PEG 0.21 · 65% evidence Relative strength 19.5/20 · Lead over its industry 33.6% · Lead over S&P 500 65.2% · 1 year 83.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 11 + 15.6 + 15.1 + 19.5 = 61.2 · What this means: Relative strength against the index is 65.2%, and revenue and profit growth are weak. 5. [argenx SE](https://www.sectoralpha.in/us/stocks/argx) ARGX · turning · Evidence leans up · 85% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.9/35 · Revenue 60.6% · Profit 22.4% · Operating margin change 5.9 points · 95% evidence Capital efficiency 17.1/25 · ROCE 18.9% · Operating margin 36.3% · 76% evidence Valuation 10.4/20 · P/E 32× · PEG 1.39 · 65% evidence Relative strength 8.4/20 · Lead over its industry -17.4% · Lead over S&P 500 2.7% · 1 year 4.7% · 100% evidence · 6 of 12 weeks ahead Exact sum: 24.9 + 17.1 + 10.4 + 8.4 = 60.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [BeOne Medicines AG](https://www.sectoralpha.in/us/stocks/onc) ONC · leader · Evidence leans up · 64% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.0/35 · Revenue 34.3% · Profit n/a · Operating margin change 12.4 points · 62% evidence Capital efficiency 13.3/25 · ROCE 13.1% · Operating margin 19.1% · 76% evidence Valuation 9.1/20 · P/E 48.3× · PEG n/a · 15% evidence Relative strength 12.2/20 · Lead over its industry -6.3% · Lead over S&P 500 16.5% · 1 year 21.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23 + 13.3 + 9.1 + 12.2 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Kymera Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/kymr) KYMR · turning · Evidence leans up · 61% evidence 57.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/35 · Revenue 100% · Profit n/a · Operating margin change 620.5 points · 62% evidence Capital efficiency 6.8/25 · ROCE -22% · Operating margin -116.3% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 16.9/20 · Lead over its industry 11% · Lead over S&P 500 36.2% · 1 year 118.4% · 100% evidence · 7 of 12 weeks ahead Exact sum: 23.9 + 6.8 + 10 + 16.9 = 57.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Spyre Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/syre) SYRE · quiet · Too little evidence to rank firmly · 56% evidence 56.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue n/a · Profit n/a · Operating margin change 999.3 points · 52% evidence Capital efficiency 8.6/25 · ROCE -24.5% · Operating margin n/a · 61% evidence Valuation 11.0/20 · P/E -8.2× · PEG n/a · 15% evidence Relative strength 12.9/20 · Lead over its industry 21.2% · Lead over S&P 500 46.6% · 1 year 328.9% · 100% evidence · 4 of 12 weeks ahead Exact sum: 23.6 + 8.6 + 11 + 12.9 = 56.1 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 9. [Moderna, Inc.](https://www.sectoralpha.in/us/stocks/mrna) MRNA · leader · Evidence leans up · 64% evidence 55.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.4/35 · Revenue -27.6% · Profit n/a · Operating margin change 80.8 points · 62% evidence Capital efficiency 6.5/25 · ROCE -28.9% · Operating margin -557.9% · 76% evidence Valuation 11.2/20 · P/E -11.6× · PEG n/a · 15% evidence Relative strength 20.0/20 · Lead over its industry 161.6% · Lead over S&P 500 205.6% · 1 year 882.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.4 + 6.5 + 11.2 + 20 = 55.1 · What this means: Relative strength against the index is 205.6%, and revenue and profit growth are weak. 10. [Krystal Biotech, Inc.](https://www.sectoralpha.in/us/stocks/krys) KRYS · quiet · Evidence leans up · 81% evidence 55.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 22.6% · Profit 65.1% · Operating margin change 8 points · 83% evidence Capital efficiency 16.1/25 · ROCE 14.4% · Operating margin 49% · 76% evidence Valuation 12.4/20 · P/E 45.4× · PEG 0.77 · 65% evidence Relative strength 4.1/20 · Lead over its industry -19% · Lead over S&P 500 0.1% · 1 year 51.7% · 100% evidence · 4 of 12 weeks ahead Exact sum: 22.4 + 16.1 + 12.4 + 4.1 = 55 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Jazz Pharmaceuticals plc](https://www.sectoralpha.in/us/stocks/jazz) JAZZ · quiet · Evidence leans up · 74% evidence 55.0 out of 100 Growth Capital Valuation Relative
12. [Royalty Pharma plc](https://www.sectoralpha.in/us/stocks/rprx) RPRX · turning · Evidence leans up · 81% evidence 53.7 out of 100 Growth Capital Valuation Relative
13. [Regeneron Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/regn) REGN · leader · Evidence leans up · 81% evidence 52.8 out of 100 Growth Capital Valuation Relative
14. [Alnylam Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/alny) ALNY · basing · Evidence leans up · 64% evidence 51.6 out of 100 Growth Capital Valuation Relative
15. [Protagonist Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ptgx) PTGX · losing its lead · Evidence leans down · 74% evidence 49.6 out of 100 Growth Capital Valuation Relative
16. [Vertex Pharmaceuticals Incorporated](https://www.sectoralpha.in/us/stocks/vrtx) VRTX · breaking out · Evidence leans down · 85% evidence 46.9 out of 100 Growth Capital Valuation Relative
17. [Bio-Techne Corporation](https://www.sectoralpha.in/us/stocks/tech) TECH · turning · Evidence leans down · 74% evidence 44.4 out of 100 Growth Capital Valuation Relative
18. [Roivant Sciences Ltd.](https://www.sectoralpha.in/us/stocks/roiv) ROIV · turning · Too little evidence to rank firmly · 60% evidence 39.5 out of 100 Growth Capital Valuation Relative
19. [Summit Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/smmt) SMMT · breaking out · Too little evidence to rank firmly · 53% evidence 39.2 out of 100 Growth Capital Valuation Relative
20. [Revolution Medicines, Inc.](https://www.sectoralpha.in/us/stocks/rvmd) RVMD · quiet · Too little evidence to rank firmly · 53% evidence 38.7 out of 100 Growth Capital Valuation Relative
21. [Madrigal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/mdgl) MDGL · quiet · Evidence leans down · 61% evidence 37.2 out of 100 Growth Capital Valuation Relative
22. [Insmed Incorporated](https://www.sectoralpha.in/us/stocks/insm) INSM · basing · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative
23. [BridgeBio Pharma, Inc.](https://www.sectoralpha.in/us/stocks/bbio) BBIO · quiet · Evidence leans down · 61% evidence 35.2 out of 100 Growth Capital Valuation Relative
24. [BioNTech SE](https://www.sectoralpha.in/us/stocks/bntx) BNTX · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
25. [BioMarin Pharmaceutical Inc.](https://www.sectoralpha.in/us/stocks/bmrn) BMRN · quiet · Most evidence points down · 81% evidence 26.8 out of 100 Growth Capital Valuation Relative
26. [Ascendis Pharma A/S](https://www.sectoralpha.in/us/stocks/asnd) ASND · turning · Too little evidence to rank firmly · 44% evidence 63.3 out of 100 Growth Capital Valuation Relative
27. Apogee Therapeutics, Inc. APGE · Too little evidence to rank firmly · 27% evidence 47.2 out of 100 Growth Capital Valuation Relative
28. Nuvalent, Inc. NUVL · Too little evidence to rank firmly · 20% evidence 41.2 out of 100 Growth Capital Valuation Relative
29. [Crinetics Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/crnx) CRNX · Too little evidence to rank firmly · 35% evidence 38.0 out of 100 Growth Capital Valuation Relative
30. Vaxcyte, Inc. PCVX · breaking out · Too little evidence to rank firmly · 47% evidence 37.4 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Biotechnology](https://www.sectoralpha.in/us/sectors/biotechnology), all 30 compared on one page. ## Which companies are close to Halozyme Therapeutics in size? Halozyme Therapeutics is the 18th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Ascendis Pharma A/S, Jazz Pharmaceuticals plc and BridgeBio Pharma, Inc. Just below it: Bio-Techne Corporation, Summit Therapeutics Inc. and Kymera Therapeutics, Inc. ### Biotechnology companies close in size

1. [Ascendis Pharma A/S](https://www.sectoralpha.in/us/stocks/asnd) $16.6 billion
2. [Jazz Pharmaceuticals plc](https://www.sectoralpha.in/us/stocks/jazz) $14.6 billion
3. [BridgeBio Pharma, Inc.](https://www.sectoralpha.in/us/stocks/bbio) $14.5 billion
4. Halozyme Therapeutics, Inc. $14 billion
5. [Bio-Techne Corporation](https://www.sectoralpha.in/us/stocks/tech) $11.4 billion
6. [Summit Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/smmt) $11.3 billion
7. [Kymera Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/kymr) $10.9 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Annaly Capital Management, Inc.](https://www.sectoralpha.in/us/stocks/nly) $14.9 billion · REIT - Mortgage
2. [Viper Energy, Inc.](https://www.sectoralpha.in/us/stocks/vnom) $14.8 billion · Oil & Gas Midstream
3. Halozyme Therapeutics, Inc. $14.8 billion
4. [Sun Communities, Inc.](https://www.sectoralpha.in/us/stocks/sui) $14.8 billion · REIT - Residential
5. [Grupo Aeroportuario del Pacífico, S.A.B. de C.V.](https://www.sectoralpha.in/us/stocks/pac) $14.7 billion · Airports & Air Services

## What else do people ask about Halozyme Therapeutics? ### What is Halozyme Therapeutics's stock price today? Halozyme Therapeutics, Inc.'s stock price is $122.96, +80.2% over the past year. The whole company is worth $14.0 B on the market. In the last 52 weeks it traded between $62 to $131; today it is 89% of the way up from the low, 45.5% above its 200-day average (as of 5 November 2026). ### What were Halozyme Therapeutics's latest quarterly results? Halozyme Therapeutics, Inc. reported revenue of $481 M and net profit of $230 M for the Jun 2026 quarter. Revenue rose 47.7% and profit rose 39.2% compared with a year earlier. Earnings per share were $1.90. The operating margin was 59.8%, 2.4 percentage points lower than a year earlier (as of 5 November 2026). ### What is Halozyme Therapeutics's market cap? Halozyme Therapeutics, Inc.'s market capitalisation is $14.0 B at a stock price of $122.96. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is Halozyme Therapeutics performing? Halozyme Therapeutics, Inc.'s share price has been rising for 20 weeks. In its latest quarter, revenue rose 47.7% and profit rose 39.2% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 20 weeks running (as of 5 November 2026). ### Will Halozyme Therapeutics's stock price go up? This page does not forecast Halozyme Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $122.96, and it has been rising for 20 weeks. Its P/E of 36.4× is higher than 95% of its own last 5 years (as of 5 November 2026). ### Where is Halozyme Therapeutics in its business cycle? Halozyme Therapeutics, Inc.'s FY25 operating margin was 58.4%, against a 5-year range of 40.7% to 62.2%: the middle of its own range, neither a peak nor a low. The latest quarter was 59.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the Halozyme Therapeutics story? The main question: the share price moved +80.2% in a year while yearly earnings per share moved −25.4%. The difference came from the market paying a higher multiple. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is Halozyme Therapeutics a stock worth studying right now? What the numbers show: Halozyme Therapeutics, Inc.'s share price has risen faster than its earnings: +80.2% in a year, against −25.4% for earnings per share. The main open question: whether earnings grow into a price that has already moved. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.